Hypertension is one of the most common medical conditions in the world, and in the United States, the Centers for Disease Control and Prevention estimates that 116 million people have it. A wide array of agents are available both as monotherapy and in fixed-dose combinations to treat the disease. RAAS inhibitors (ACE inhibitors and ARBs), diuretics, and calcium channel blockers are the most commonly used first-line agents. The majority of antihypertensive agents are generically available and thus are cost-effective. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated hypertensive patients receive pharmacotherapy in the United States.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Noden Pharma, Pfizer, Novartis
Key drugs: ACE inhibitors, Beta blockers, ARBs
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.